To develop an all-injectable long-acting HIV therapy, Frontier Biotech has designed and developed a combination regimen of Aikening™ (Albuvirtide) and 3BNC117, a recombinant fully human monoclonal antibody with broadly neutralizing effects on HIV-1 virus.

3BNC117 is one of the most clinically advanced anti-HIV broadly neutralizing antibodies (bNAbs), which not only exhibits long-acting anti-HIV efficacy, but also has been clinically proven to elicit human immune response to curtail HIV-infected cells, resulting in delayed viral rebound (or preventing viral remission). 3BNC117 has exhibited an excellent safety profile in both healthy and HIV-1-infected individuals.

3BNC117 specifically binds to the CD4 binding site (CD4bs) within HIV-1 envelope glycoprotein 120 (gp120) and its mechanism of action is complementary and potentially synergistic with Aikeing™, therefore the combination regimen is potentially effective for major and drug-resistant viral strains.

If you are interested in access to Frontier's investigational drugs, please find the expanded access policy here.

.